MDM2 rs2279744 polymorphism and endometrial cancer: A meta-analysis

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3167-3170

  Wang, Li Hong ^a,b   Wang, Xu ^a   Xu, Wen Ting ^b   Hu, Ya Li ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b Zhangjiagang Hospital of Traditional Chinese Medicine Group Corporation   (China)

Author keywords

Endometrial cancer; MDM2 polymorphism; Meta analysis

Indexed keywords

PROTEIN MDM2;

ARTICLE; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; ENDOMETRIUM CANCER; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HOMOZYGOTE; HUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL;

ENDOMETRIAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RISK;

EID: 84898834869     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1413-8     Document Type: Article

References (16)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90.
2. Zhou X, Gu Y, Wang DN, Ni S, Yan J. Eight functional polymorphisms in the estrogen receptor 1 gene and endometrial cancer risk: a meta-analysis. PLoS One. 2013;8(4):e60851.
3. Wang Y, Cui M, Zheng L. Genetic polymorphisms in the estrogen receptor-α gene and the risk of endometrial cancer: a meta-analysis. Acta Obstet Gynecol Scand. 2012;91(8):911-6.
4. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591-602.
5. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, et al. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol. 2009;113(1):109-14.
6. Knappskog S, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC. MoMaTEC study group, et al. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer. 2012;48(13):1988-96.
7. Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, et al. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell. 2009;22(4):101-6.
8. Terry K, McGrath M, Lee IM, Buring J, De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(4):983-6.
9. Ueda M, Yamamoto M, Nunobiki O, Toji E, Sato N, Izuma S, et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell. 2009;22(2):49-54.
10. Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol. 2007;104(3):660-4.
11. Yoneda T, Kuboyama A, Kato K, Ohgami T, Okamoto K, Saito T, et al. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. Oncol Rep. 2013;30(1):25-34.
12. Zaja̧c A, Stachowiak G, Pertyński T, Romanowicz H, Wilczyński J, Smolarz B. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women. Pol J Pathol. 2012;63(4):278-83.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
14. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-29.
15. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
16. Li Y, Zhao H, Sun L, Huang L, Yang Q, Kong B. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis. Hum Cell. 2011;24(2):57-64.